The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Multicenter phase II trial to investigate safety and efficacy of an adjuvant therapy with gemcitabine and cetuximab in patients with R0 or R1 resected pancreatic cancer.
H. Fensterer
Honoraria - Roche
Expert Testimony - Roche
Other Remuneration - Roche
C. Schade-Brittinger
No relevant relationships to disclose
H. Mueller
No relevant relationships to disclose
B. Schupfner
No relevant relationships to disclose
J. Fass
No relevant relationships to disclose
U. Lindig
No relevant relationships to disclose
U. Settmacher
No relevant relationships to disclose
M. P. Ebert
No relevant relationships to disclose
M. Kornmann
No relevant relationships to disclose
R. Hofheinz
Honoraria - Merck KGaA
Research Funding - Merck KGaA
E. Endlicher
No relevant relationships to disclose
C. Brendel
No relevant relationships to disclose
P. J. Barth
No relevant relationships to disclose
D. K. Bartsch
No relevant relationships to disclose
T. M. Gress
No relevant relationships to disclose